Denali Therapeutics Inc. (NASDAQ:DNLI) Receives $34.25 Average Target Price from Analysts

Denali Therapeutics Inc. (NASDAQ:DNLI) has earned an average rating of “Moderate Buy” from the sixteen analysts that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $34.25.

Several research analysts have recently weighed in on the stock. The Goldman Sachs Group increased their price objective on shares of Denali Therapeutics from $35.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, March 26th. Deutsche Bank Aktiengesellschaft set a $31.00 target price on shares of Denali Therapeutics in a research report on Friday, May 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Denali Therapeutics in a research report on Monday, April 20th. Robert W. Baird increased their target price on shares of Denali Therapeutics from $32.00 to $34.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 7th. Finally, Wall Street Zen raised shares of Denali Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 9th.

Institutional Trading of Denali Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of DNLI. Headlands Technologies LLC acquired a new stake in Denali Therapeutics during the 2nd quarter worth approximately $26,000. Johnson Financial Group Inc. acquired a new stake in Denali Therapeutics during the 3rd quarter worth approximately $29,000. State of Wyoming acquired a new stake in Denali Therapeutics during the 2nd quarter worth approximately $29,000. Fifth Third Bancorp acquired a new stake in Denali Therapeutics in the first quarter valued at approximately $55,000. Finally, Aster Capital Management DIFC Ltd acquired a new stake in Denali Therapeutics in the fourth quarter valued at approximately $57,000. Institutional investors and hedge funds own 92.92% of the company’s stock.

Denali Therapeutics Price Performance

NASDAQ:DNLI opened at $24.77 on Friday. The firm has a market cap of $3.93 billion, a price-to-earnings ratio of -8.60 and a beta of 1.03. The company has a current ratio of 9.28, a quick ratio of 9.28 and a debt-to-equity ratio of 0.01. The company’s 50-day moving average is $20.30 and its two-hundred day moving average is $19.66. Denali Therapeutics has a 12-month low of $12.58 and a 12-month high of $25.31.

Denali Therapeutics (NASDAQ:DNLI) last released its earnings results on Thursday, May 7th. The company reported ($0.69) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.04. During the same quarter in the previous year, the business earned ($0.78) earnings per share. Research analysts expect that Denali Therapeutics will post -2.77 EPS for the current year.

About Denali Therapeutics

Denali Therapeutics is a clinical?stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine?rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti?TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.